Odimma Therapeutics and myNEO Therapeutics will partner to identify personalized targets for clinical development of DNA-based cancer vaccine therapy.

The myNEO Therapeutics project team is excited to have Odimma as our newest partner, and to be able to enter the field of DNA cancer vaccines. We are fully convinced that a more patient-centric approach of evaluating and targeting the tumor will be an essential part of the future, and different parallel revolutions have enabled to incorporate it in a cost-efficient and logistically feasible process. The myNEO Therapeutics’ antigen discovery technology has the key to drive personalized immunotherapy towards clinical success. The Odimma technology provides an innovative new avenue to bring the breakthroughs of personalized tumor targeting models to the patients.